XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Compare volatility and returns in retirement index funds to strike a balance between potential growth and risk control for sustainable withdrawals.
24,638 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
When a high-profile investor places big bets in AI leaders, markets take notice. This piece breaks down the latest mo...
Feeling stretched between paydays? These seven practical tips stop living paycheck and help you create a cushion, cut...
When the Oscars fall silent on a beloved figure, families face more than grief—they face financial questions. This pi...
Two 2x MicroStrategy ETFs, MSTX and MSTU, are under renewed scrutiny as volatility tests the funds' synthetic exposur...
Retirees face a tough choice as Netflix and T-Mobile trade lower on the year. This analysis weighs dividends, cash fl...
U.S. regulators say a crypto venture raised about $22 million from more than 380 investors, yet only a sliver went to...
Ethereum sits just above $2,100 as on-chain data shows exchange reserves shrinking to levels not seen since 2016, wit...
Could oil trend toward $60 a barrel by 2027? This article analyzes the scenario, the forces at play, and concrete sto...
A year ago, a $1,000 investment in Newmont could have grown nicely as gold and miners moved. This article breaks down...
As the S&P 500 retreats, two growth-focused ETFs show resilience. This report breaks down why FELG and QQQ are defyin...
Institutional funds are piling into crypto stocks as a regulated way to gain exposure to digital assets. The question...